

Luxembourg, December 2024

**Public**

## Environmental and Social Data Sheet<sup>1</sup>

### Overview

Project Name:	GREENLIGHT BIO (IEU LS)
Project Number:	2023-0807
Country:	Spain
Project Description:	The project concerns the research & development, registration, commercialisation and manufacturing of a pipeline of innovative active substances and plant protection products for plant health and bee health.
EIA required:	No
Invest EU sustainability proofing required	Yes
Project included in Carbon Footprint Exercise <sup>2</sup> :	No

### Environmental and Social Assessment

#### Environmental Assessment

The proposed operation concerns the financing of the promoter's research, development, and innovation (RDI) activities over the period 2024 - 2027. The RDI programmes are aiming for EU registration of a pipeline of products based on innovative active substances and plant protection products of Ribonucleic acid interference (RNAi)-based and other biocontrol solutions for plant health (Insecticide, herbicide, fungal) and bee health. RNAi is a naturally occurring process in all living cells aimed at modulating the production of proteins to ensure that protein synthesis occurs only when needed.

The project will primarily address the negative environmental externalities typically generated by the current use and risk of the most harmful chemical pesticides, in the context of increase pressure of pest due to climate change. If successful, the project will generate environmental benefits as it should

<sup>1</sup> The information contained in the document reflects the requirement related to the environmental, social and climate information to be provided to Investment Committee as required by the Invest EU Regulation and it represents the equivalent of the information required in the template of the InvestEU sustainability proofing summary

<sup>2</sup> Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO<sub>2</sub>e/year absolute (gross) or 20,000 tonnes CO<sub>2</sub>e/year relative (net) – both increases and savings.



Luxembourg, December 2024

displace traditional active molecules with some candidates for substitution under the EU legislative framework.

The RDI activities will be carried out within existing RDI facilities, greenhouses, or field trials in a controlled environment, located in Spain and other EU countries as well as in the US. They do not involve the construction of new facilities nor the modification of existing RDI facilities that would fall under the provisions of the Directive 2011/92/EU as amended by the Directive 2014/52/EU. Research facilities have valid operation permits approved by the national competent authorities.

### **Climate Assessment**

The project is not sensitive to climate change and its output is susceptible to generate significant externalities in the areas of environmental protection (reduced environmental footprint of agricultural activities), food security, and climate resilience in agricultural land management.

It is expected to develop innovative products allowing safer and environmentally friendly farming practices to deal with multiple resistances (Insect, weed or fungi), pesticide withdrawals in the EU, including for chemicals classified by the EU legislation as candidates for substitution.

Most of the RDI efforts target demonstrating that RNAi based products degrade quickly in the environment, leaving low or no residues.

### **EIB Paris Alignment for Counterparties (PATH) Framework**

The counterparty Greenlight is not within the scope of the PATH and it does not operate in high emitting sectors nor in a context of high climate vulnerability. Hence, the counterparty is screened out of the PATH framework.

### **Other Environmental and Social Aspects**

The bank's foreseen investment only concerns RDI costs related to the registration in the EU of a pipeline of products and solutions for plant health and bee health. The programme and facilities will maintain a Quality Management System (QMS) and work according to the principle of Good Research and Laboratory Practices.

## **Conclusions and Recommendations**

**Sustainability proofing:** the project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environment, climate and social (ECS) information the project is deemed to have low residual ECS risks and impacts. No further sustainability proofing is required.

### **Undertakings**

The Promoter shall inform the Bank about any change/modification/extension of the project that could trigger an EIA and/or IED permitting process, following



Luxembourg, December 2024

EIA directive 2011/92/EU as amended by Directive, 2014/52/EU and/or Industrial Emissions Directive 2010/75/EU and submit the relevant assessment reports and permits to the Bank.

Subject to the above-mentioned contractual undertakings, the project is acceptable for EIB financing in environmental and social terms.